Bisker-Leib Vered 4/A
4/A · Compass Therapeutics, Inc. · Filed Feb 23, 2022
Insider Transaction Report
Form 4/AAmended
Bisker-Leib Vered
Chief Operating Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-02-18+500,000→ 500,000 totalExercise: $2.40Exp: 2032-02-17→ Common Stock (500,000 underlying)
Footnotes (1)
- [F1]The options vest over 48 substantially equal monthly installments starting 03/17/2022.